1. Home
  2. AEI vs SCLX Comparison

AEI vs SCLX Comparison

Compare AEI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

HOLD

Current Price

$1.35

Market Cap

54.1M

Sector

Real Estate

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.67

Market Cap

48.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEI
SCLX
Founded
2014
2011
Country
United States
United States
Employees
N/A
34
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.1M
48.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
AEI
SCLX
Price
$1.35
$6.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.9K
109.6K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,238,200.00
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$4.20
52 Week High
$4.55
$34.27

Technical Indicators

Market Signals
Indicator
AEI
SCLX
Relative Strength Index (RSI) 40.37 46.38
Support Level $1.22 $5.88
Resistance Level $2.10 $7.77
Average True Range (ATR) 0.14 0.92
MACD 0.00 -0.08
Stochastic Oscillator 36.88 36.26

Price Performance

Historical Comparison
AEI
SCLX

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: Real Estate, Digital Transformation Technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: